LOCAL PROVIDER DIRECTORY
Find a dentist
Search by name or specialty, then choose a city and region or enter a ZIP / postal code.
Choose a location to keep your results local.
Local Health Alerts
CMS proposes faster prior-authorization decisions for drugs
CMS has proposed shorter deadlines and more electronic processing for prescription-drug prior authorizations in several federal health coverage programs. The plan would not end prior authorization, but it could reduce delays and improve transparency around denials and appeals.
FDA flags Class I Omnipod 5 pod recall over insulin leak risk
The FDA says certain Omnipod 5 pods are part of a Class I recall because a manufacturing defect may let insulin leak inside the pod. The notice says affected users should stop using impacted pods, check lot numbers, and switch to unaffected pods…
Why Measles Is Surging Again in the U.S., and What Families Should Do Now
Measles is climbing again in 2026, and the most useful response for families is simple: know the signs, check vaccination status, and follow local public-health guidance after exposure. The outbreak is active, but it remains preventable with timely vaccination and fast action when…
When Worry Becomes an Anxiety Disorder: How to Tell the Difference and What to Do Next
Worry is common, but anxiety can cross the line when it lasts, feels hard to control, and starts disrupting daily life. Here’s how to spot the difference, what short-term self-care may help, and when to reach out for professional care.
CMS proposes electronic prior authorization for drugs in health plans
CMS has proposed a new rule that would expand electronic prior authorization to drugs and add faster decision timelines for some plans. The change is not final yet, and the details could still change after public comment closes on June 15, 2026.
FDA Proposes to Pull Popular Weight-Loss Drugs From Compounding Bulks List
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a move that could affect some compounded GLP-1 products. Patients using compounded versions should not make changes on their own; they should check with the prescriber or pharmacist about…
Why Older Adults Are Falling More Often — and What Helps
Falls remain the leading cause of injury death for adults 65 and older, and recent CDC data show the death rate is still rising. The good news: many falls can be prevented with a mix of eye care, home changes, safer medicine use,…
FDA’s Updated “Healthy” Label Aims to Help Shoppers Compare Foods
The FDA has updated when food packages can use the word “healthy.” The claim now better reflects current nutrition guidance, but it is still only a shortcut. Shoppers should keep checking the Nutrition Facts label for serving size, sodium, added sugars, and saturated…
Why a New USPSTF Recommendation on IPV Screening Matters
The U.S. Preventive Services Task Force says clinicians should screen women of reproductive age, including pregnant and postpartum patients, for intimate partner violence. The same update says evidence is still insufficient to recommend routine screening for caregiver abuse in older or vulnerable adults.
Newborn Opioid Withdrawal Trial May Reduce Medication Use
An NIH-funded study suggests a symptom-based approach may help newborns with opioid withdrawal recover sooner and spend less time on medicine. The findings are promising, but the approach was tested in a specific hospital setting and is not yet universal practice.
CMS proposes faster electronic prior authorization for drugs
CMS has proposed changes that could make prior authorization for certain drugs faster and more electronic for people in Medicare Advantage, Medicaid managed care, CHIP, and Marketplace plans. The rule is still only proposed, and details can change after public comment closes on…
FDA tightens rules on compounded GLP-1 drugs as shortages ease
The FDA is moving to narrow when compounders can make semaglutide, tirzepatide, and liraglutide as national shortages improve. For people using compounded GLP-1 medicines, the practical next step is to check exactly what product they have and confirm any changes with a clinician…
